sunitinib
Showing 26 - 50 of 196
Gastrointestinal Stromal Tumors Trial in Tokyo (Pimitespib, Imatinib, Sunitinib)
Recruiting
- Gastrointestinal Stromal Tumors
- Pimitespib
- +2 more
-
Tokyo, JapanA site selected by Taiho Pharmaceutical Co., Ltd.
Aug 4, 2022
Small Cell Lung Cancer Trial in United States (irinotecan, Carboplatin, sunitinib)
Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma Trial in Canada, United States (Nivolumab, Pazopanib,
Completed
- Renal Cell Carcinoma
- Clear-cell Metastatic Renal Cell Carcinoma
- Nivolumab
- +3 more
-
Duarte, California
- +13 more
Nov 30, 2021
Type B3 Thymoma, Thymic Carcinoma Trial in Milan (Sunitinib)
Recruiting
- Type B3 Thymoma
- Thymic Carcinoma
- Sunitinib
-
Milan, ItalyNational Cancer Institute
Jun 8, 2021
Carcinoma, Renal Cell Trial in China, Korea, Republic of, Taiwan (Pazopanib, Sunitinib)
Completed
- Carcinoma, Renal Cell
- Pazopanib
- Sunitinib
-
Guangzhou, Guangdong, China
- +20 more
Dec 6, 2021
Kidney Cancer Trial in Boston, Houston, Salt Lake City (Everolimus, Sunitinib)
Glioblastoma Multiforme, Glioblastoma, Adult, Glioblastoma Trial in Amsterdam, Groningen, Nijmegen (Sunitinib, Lomustine)
Recruiting
- Glioblastoma Multiforme
- +4 more
- Sunitinib
- Lomustine
-
Amsterdam, Netherlands
- +2 more
Apr 14, 2021
Advanced Rare Tumours Trial in Canada (Sunitinib, Temsirolimus)
Active, not recruiting
- Advanced Rare Tumours
- Sunitinib
- Temsirolimus
-
Calgary, Alberta, Canada
- +16 more
Mar 17, 2022
Metastatic Renal Cell Carcinoma Who Received Sunitinib After 1st
Completed
- Metastatic Renal Cell Carcinoma (mRCC)
- sunitinib
-
Calgary, Alberta, CanadaUniversity of Calgary
Mar 8, 2021
Carcinoma, Carcinoma, Renal Cell, Kidney Tumors Trial in Worldwide (Savolitinib, Sunitinib)
Active, not recruiting
- Carcinoma
- +7 more
- Savolitinib
- Sunitinib
-
La Jolla, California
- +58 more
Jan 13, 2023
Sunitinib In Chinese Progressive Advanced Or Metastatic
Active, not recruiting
- Pancreatic Neuroendocrine Tumors
- sunitinib
-
Hefei, Anhui, China
- +15 more
Oct 19, 2021
NSCLC, Carcinoma, Small Cell Lung, Carcinoma, Thymic Trial run by the National Cancer Institute (NCI) (AZD6244, MK-2206,
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- AZD6244
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Carcinoma, Renal Cell Trial in Durham (Sunitinib)
Completed
- Carcinoma, Renal Cell
- Sunitinib
-
Durham, North CarolinaDuke Cancer Institute
Nov 23, 2020
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
Completed
- Renal Cell Cancer Metastatic
- +2 more
- Sunitinib
-
Berlin, GermanyExperimental and Clinical Research Center, Clinical Research Uni
Jan 25, 2021
Renal Cell Carcinoma Who Received First-Line Sunitinib
Completed
- Metastatic Renal Cell Carcinoma
- Sunitinib
-
Calgary, Alberta, CanadaUniversity of Calgary
Feb 19, 2021
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 Trial in
Recruiting
- Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
- Biological : Toripalimab Drug: Axitinib
- sunitinib
-
Beijing, ChinaBeijing Cancer Hospital
Jan 24, 2021
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in Canada (Olaparib, Dasatinib, Nivolumab plus Ipilimumab)
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Olaparib
- +13 more
-
Edmonton, Alberta, Canada
- +9 more
Jan 9, 2023
Clear Cell Renal Carcinoma Trial in Spain (Sunitinib)
Completed
- Clear Cell Renal Carcinoma
- Sunitinib
-
L'Hospitalet de Llobregat, Barcelona, Spain
- +8 more
Nov 12, 2020
Gastrointestinal Stromal Tumors Trial in Worldwide (Masitinib, Sunitinib)
Completed
- Gastrointestinal Stromal Tumors
- Masitinib
- Sunitinib
-
Saint Louis, Missouri
- +4 more
Dec 7, 2020